SCHEMBL148250

SCHEMBL148250

O=C(Nc1ccc2c(c1)[nH]c1ccccc12)c1ccncc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.61
KDM4E B2RXH2 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
ALDH1A1 P00352 1/20 0.61
HPGD P15428 1/20 0.61
HSD17B10 Q99714 1/20 0.61
KCNK3 O14649 1/20 0.57
GAA P10253 1/20 0.55
HTT P42858 1/20 0.55
NPY5R Q15761 1/20 0.55
MAOA P21397 1/20 0.54
POLB P06746 1/20 0.52
MAPK1 P28482 1/20 0.52
BRD4 O60885 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
ROCK2 O75116 1/20 0.52
JAK2 O60674 1/20 0.51
TYK2 P29597 1/20 0.51
MTNR1A P48039 1/20 0.51
MTNR1B P49286 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4725184 0.92 NPY5R (0.65) LMNAKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL154006 0.86 RAB9A (0.63) LMNAKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL145957 0.81 GRM4 (0.58) KDM4ESMN1; SMN2KCNK3MAOAMTNR1A
SCHEMBL148105 0.81 RAB9A (0.62) KDM4ESMN1; SMN2ALDH1A1KMT2A
SCHEMBL15532319 0.80 BRD4 (0.77) KDM4ESMN1; SMN2ALDH1A1KCNK3NPY5R
SCHEMBL149312 0.80 RAB9A (0.62) LMNASMN1; SMN2ALDH1A1HTTMAOA
SCHEMBL3696476 0.78 MAOA (0.64) KDM4EALDH1A1GAAMAOABRD4
SCHEMBL22616930 0.77 MAOA (0.86) KDM4EALDH1A1HPGDMAOAPOLB
SCHEMBL25970577 0.77 NPC1 (0.65) SMN1; SMN2KCNK3MAOAPOLBBRD4
SCHEMBL19242053 0.74 GAA (1.00) LMNAKDM4ESMN1; SMN2ALDH1A1KCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 LMNA 4636/4885KDM4E 733/4885SMN1; SMN2 4428/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 LMNA 4636/4885KDM4E 733/4885SMN1; SMN2 4428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.